EMAIL THIS PAGE TO A FRIEND

PloS one

Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression.


PMID 24801981

Abstract

Hypoxia and inflammation are strictly interconnected both concurring to prostate cancer progression. Numerous reports highlight the role of tumor cells in the synthesis of pro-inflammatory molecules and show that hypoxia can modulate a number of these genes contributing substantially to the increase of cancer aggressiveness. However, little is known about the importance of the tumor phenotype in this process. The present study explores how different features, including differentiation and aggressiveness, of prostate tumor cell lines impact on the hypoxic remodeling of pro-inflammatory gene expression and malignancy. We performed our studies on three cell lines with increasing metastatic potential: the well differentiated androgen-dependent LNCaP and the less differentiated and androgen-independent DU145 and PC3. We analyzed the effect that hypoxic treatment has on modulating pro-inflammatory gene expression and evaluated the role HIF isoforms and NF-kB play in sustaining this process. DU145 and PC3 cells evidenced a higher normoxic expression and a more complete hypoxic induction of pro-inflammatory molecules compared to the well differentiated LNCaP cell line. The role of HIF1α and NF-kB, the master regulators of hypoxia and inflammation respectively, in sustaining the hypoxic pro-inflammatory phenotype was different according to cell type. NF-kB was observed to play a main role in DU145 and PC3 cells in which treatment with the NF-kB inhibitor parthenolide was able to counteract both the hypoxic pro-inflammatory shift and HIF1α activation but not in LNCaP cells. Our data highlight that tumor prostate cell phenotype contributes at a different degree and with different mechanisms to the hypoxic pro-inflammatory gene expression related to tumor progression.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA003928
Anti-CDC37 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2100543
Anti-DCTN2 antibody produced in rabbit, affinity isolated antibody
HPA039715
Anti-DCTN2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA040040
Anti-DCTN2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA019693
Anti-LSP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101400
Anti-LSP1 antibody produced in rabbit, affinity isolated antibody
SAB1410762
Anti-LSP1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
HPA026745
Anti-POLD2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101838
Anti-POLD2 antibody produced in rabbit, affinity isolated antibody
SAB1410988
Anti-POLD2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
EHU036851 MISSION® esiRNA, esiRNA human NTS (esiRNA1)
EHU023471 MISSION® esiRNA, esiRNA human NT5E (esiRNA1)
SIHP0370 MISSION® Human Phosphatase, NT5E siRNA1, Nano Scale 250 pmol
SIHP0371 MISSION® Human Phosphatase, NT5E siRNA2, Nano Scale 250 pmol
SIHP0372 MISSION® Human Phosphatase, NT5E siRNA3, Nano Scale 250 pmol
P0667
Parthenolide, ≥98% (HPLC)
C15H20O3